MOLECULAR DISCOVERY LIMITED ABBREVIATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2002



SOBELL RHODES

Chartered Accountants 215 Marsh Road Pinner Middlesex HA5 5NE

MOLECULAR DISCOVERY LIMITED ABBREVIATED FINANCIAL STATEMENTS YEAR ENDED 31 MARCH 2002

CONTENTS	PAGES
Abbreviated balance sheet	1
Notes to the abbreviated financial statements	2 to 3

MOLECULAR DISCOVERY LIMITED

ABBREVIATED BALANCE SHEET

31 MARCH 2002

		2002		2001 (restated)	
	Note	£	£	£	£
FIXED ASSETS	2				
Tangible assets			2,488		1,977
CURRENT ASSETS					
Debtors		24,203		21,511	
Cash at bank and in hand		666,528		304,240	
		690,731		325,751	
CREDITORS: Amounts falling du	e				
within one year		341,231		193,893	
NET CURRENT ASSETS			349,500		131,858
TOTAL ASSETS LESS CURRENT	T LIABILI	TIES	351,988		133,835
CAPITAL AND RESERVES					
Called-up equity share capital	4		5		5
Profit and Loss Account			351,983		133,830
SHAREHOLDERS' FUNDS			351,988		133,835

The directors are satisfied that the company is entitled to exemption from the provisions of the Companies Act 1985 (the Act) relating to the audit of the accounts for the year by virtue of section 249A(1), and that no member or members have requested an audit pursuant to section 249B(2) of the Act.

The directors acknowledge their responsibilities for:

- (i) ensuring that the company keeps proper accounting records which comply with section 221 of the Act, and
- (ii) preparing accounts which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the financial year in accordance with the requirements of section 226, and which otherwise comply with the requirements of the Act relating to financial statements, so far as applicable to the company.

These accounts have been prepared in accordance with the special provisions for small companies under Part VII of the Companies Act 1985.

These financial statements were approved by the directors on the 25 February 2003 and are signed on their behalf by:

DR G CRUCIANI

Coneron"

Director

The notes on pages 2 to 3 form part of these financial statements.

MOLECULAR DISCOVERY LIMITED

NOTES TO THE ABBREVIATED FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2002

1. ACCOUNTING POLICIES

Basis of accounting

The financial statements have been prepared under the historical cost convention, and in accordance with the Financial Reporting Standard for Smaller Entities (effective March 2000).

Turnover

The turnover shown in the profit and loss account represents amounts invoiced during the year, exclusive of Value Added Tax.

Depreciation

Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Fixtures & Fittings

- 10% on cost

Equipment

25% on cost

Royalties payable

Royalties payable represent the expense payable to the holding company, for the use of exploitation rights purchased from the former shareholders of the company, by the holding company.

2. FIXED ASSETS

	Tangible
	Assets
	£
COST	
At 1 April 2001	2,636
Additions	1,560
44.21 Manual 2002	4 106
At 31 March 2002	4,196
DEPRECIATION	
At 1 April 2001	659
Charge for year	1,049
At 31 March 2002	1,708
At 51 March 2002	
NET BOOK VALUE	
At 31 March 2002	2,488
At 51 March 2002	2,400
At 31 March 2001	1,977

MOLECULAR DISCOVERY LIMITED

NOTES TO THE ABBREVIATED FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2002

3. RELATED PARTY TRANSACTIONS

Molecular Discovery Limited related parties, the nature of the relationship and the extent of the transactions with them are summarised below:

Diplema 463 Limited

The company is a wholly owned subsidiary of Molecular Discovery Limited.

During the year the company paid Royalties in the amount of £54,504(2001: £53,534) and Dividends in the amount of £45,000 (2001: £45,000) to Diplema 463 Limited.

At the period end, the company owed £112,830 (2001: £80,911) to Diplema 463 Limited.

4. SHARE CAPITAL

Authorised share capital:

•	2002	2001
		(restated)
	£	£
100 Ordinary shares of £1 each	100	100
Allotted colled up and fully noid.		
Allotted, called up and fully paid:		2001
	2002	2001
		(restated)
	£	£
Ordinary share capital	5	5
•		<u>*</u>

5. ULTIMATE PARENT COMPANY

The ultimate parent company is Diplema 463 Limited, a company registered in England and Wales.